Single-Center Investigation of the Pharmacokinetics of WCK 4282 (Cefepime-Tazobactam Combination) in Renal Impairment

Abstract

WCK 4282 is a combination product of cefepime (FEP) and tazobactam (TAZ) in a 1:1 ratio currently under development for the treatment of multidrug-resistant Gram-negative bacterial infections. We investigated the effect of renal impairment on the pharmacokinetics (PK) and safety of WCK 4282 in 48 subjects with various degrees of renal function. Subjects were categorized on the basis of their Cockcroft-Gault equation-estimated creatinine clearance (CLCR). We enrolled 6 subjects each into those with mild (CLCR, 60 to <90 ml/min), moderate (CLCR, 30 to <60 ml/min), or severe (CLCR, <30 ml/min) renal impairment and those with end-stage renal disease (ESRD) requiring hemodialysis and 24 healthy control subjects (CLCR, ≥90 ml/min). Healthy subjects and subjects with mild and moderate renal impairment received a single 90-min infusion of 4 g of WCK 4282 (2 g FEP and 2 g TAZ). Subjects with severe renal impairment and ESRD received 2 g of WCK 4282 (1 g FEP and 1 g TAZ) over 90 min. The plasma exposure of FEP-TAZ increased as renal function decreased. In subjects with mild, moderate, and severe renal impairment and ESRD, the mean exposure (area under the plasma concentration versus time curve from time zero extrapolated to infinity) of FEP and TAZ increased by 1.3- and 1.2-fold, 2.3- and 2.3-fold, 4.7- and 4.0-fold, and 8.5- and 11.6-fold, respectively. The urinary recovery of FEP and TAZ decreased with increasing renal impairment. There were no adverse events reported during the study. The findings suggest that dose adjustments for WCK 4282 will be required according to the degree of renal impairment. A single infusion of WCK 4282 was found to be safe and well tolerated in subjects with normal and impaired renal function. (This study has been registered at ClinicalTrials.gov under identifier NCT02709382.)

Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria

“…To address this limitation, Wockhardt are reformulating cefepime/tazobactam (WCK 4282) as a proprietary 2+2g q8h combination, delivering 6g/tazobactam/day, with a 90minute infusion time to maximise time above MIC. [8] The approach fits well within the concept of 'repurposing' old antibiotics to overcome resistance [9] and the high-dose combination is now entering Phase III trials. We sought to compare its activity in vitro with that of available tazobactam combinations against problem Gram-negative bacteria sent to the UK national reference laboratory.…”

Ensuring robustness in the quality of antibiotic susceptibility test discs for four novel antibiotics

“…FPZ is a novel mode of action‐combination antibiotic consisting of FEP and proprietary β‐lactam enhancer antibiotic Zidebactam (ZID) being developed for multidrug resistant/extensively drug‐resistant gram‐negative infections. It has completed phase I study in USA (ClinicalTrials.gov Identifier: NCT02707107 and NCT02684347) (Preston, Mamikonyan, DeGraff, et al, 2019).…”